{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:48:14Z","timestamp":1784396894055,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Science and Technology Program of Guangzhou, China","award":["SL2023A03J01162"],"award-info":[{"award-number":["SL2023A03J01162"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To investigate the role and mechanism of miR-342 and FOXP1 on hepatocellular carcinoma cells. QRT-PCR was applied to determine the expression of miR-342, FOXP1 and MYCBP in normal hepatocyte cell lines (NHC), hepatocellular carcinoma cell lines (HEK-293\u00a0T) and human hepatocellular carcinoma cell lines (HepG2, MHCC97-L, Huh7 and SMMC7721). After knockdown or over-expression of miR-342 and FOXP1 in HepG2 cells respectively, cell proliferation and cell viability were measured using MTT assay and colony formation assay. Flow cytometry was adopted to test for apoptosis. Dual luciferase gene reporter assays were performed to validate the target relationship between FOXP1and miR-342 or MYCBP. The level of apoptosis-related proteins cleaved-caspase-3, Bcl-2 and Bax were measured by western blot. Compared with NHC, miR-342 expression was decreased and FOXP1 expression was up-regulated in hepatocellular carcinoma cell lines. MiR-342 could target and negatively regulate FOXP1. FOXP1 could promote the proliferation of hepatocellular carcinoma cells, positively regulate the expression of c-Caspase-3, Bax, negatively regulate Bcl-2 and inhibit apoptosis. FOXP1 can also target and positively regulate MYCBP. The expression of MYCBP was up-regulated in the hepatocellular carcinoma cell lines, while overexpression of miR-342 decreased MYCBP expression promoted by overexpression of FOXP1. MiR-342 can inhibit FOXP1\/MYCBP signaling axis to regulate the members of Caspase-3 and Bcl-2 family to inhibit the proliferation and promote apoptosis of hepatocellular carcinoma cells.<\/jats:p>","DOI":"10.1093\/toxres\/tfae149","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T08:08:21Z","timestamp":1734422901000},"source":"Crossref","is-referenced-by-count":3,"title":["Microrna-342 inhibits hepatocellular carcinoma cell proliferation and promotes apoptosis through the FOXP1\/MYCBP Signaling Axis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2184-0693","authenticated-orcid":false,"given":"Yanling","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology , The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province,","place":["China"]},{"name":"The First Clinical School of Guangzhou University of Chinese Medicine , No. 1 Guangming East Road, Zengcheng District, Guangzhou 510000 Guangdong Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Da Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology , The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province,","place":["China"]},{"name":"The First Clinical School of Guangzhou University of Chinese Medicine , No. 1 Guangming East Road, Zengcheng District, Guangzhou 510000 Guangdong Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian Ya","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology , The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province,","place":["China"]},{"name":"The First Clinical School of Guangzhou University of Chinese Medicine , No. 1 Guangming East Road, Zengcheng District, Guangzhou 510000 Guangdong Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology , The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province,","place":["China"]},{"name":"The First Clinical School of Guangzhou University of Chinese Medicine , No. 1 Guangming East Road, Zengcheng District, Guangzhou 510000 Guangdong Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology , The Fourth Affiliated Hospital of Guangzhou Medical University, No. 232, Outer Ring East Road, Panyu District, Guangzhou 510000 Guangdong Province,","place":["China"]},{"name":"The First Clinical School of Guangzhou University of Chinese Medicine , No. 1 Guangming East Road, Zengcheng District, Guangzhou 510000 Guangdong Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"issue":"7","key":"2024121708080988100_ref1","first-page":"101","article-title":"The diagnosis and treatment of hepatocellular carcinoma","volume":"111","author":"Malek","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"2024121708080988100_ref2","first-page":"1","article-title":"Report of cancer incidence and mortality in different areas of China, 2015","volume":"28","author":"Sun","year":"2019","journal-title":"China cancer"},{"issue":"2","key":"2024121708080988100_ref3","first-page":"549","article-title":"Liver resection and transplantation in the management of hepatocellular carcinoma: a review","volume":"4","author":"Kassahun","year":"2006","journal-title":"Exp Clin Transplant"},{"key":"2024121708080988100_ref4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.dnarep.2018.08.022","article-title":"The comings and goings of PARP-1 in response to DNA damage","volume":"71","author":"Pascal","year":"2018","journal-title":"DNA Repair (Amst)"},{"issue":"5","key":"2024121708080988100_ref5","first-page":"2742","article-title":"Serum miR-342-3p is a novel diagnostic and prognostic biomarker for non-small cell lung cancer","volume":"11","author":"Qin","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2024121708080988100_ref6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbcan.2017.06.004","article-title":"BCL2: a promising cancer therapeutic target","volume":"1868","author":"Radha","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"4","key":"2024121708080988100_ref7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/cdd.2014.216","article-title":"Old, new and emerging functions of caspases","volume":"22","author":"Shalini","year":"2015","journal-title":"Cell Death Differ"},{"key":"2024121708080988100_ref8","first-page":"355","article-title":"Gene expression in oligodendroglial tumors","volume":"34","author":"Shaw","year":"2011","journal-title":"Cancer Sci"},{"issue":"3","key":"2024121708080988100_ref9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: BCL-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch Toxicol"},{"key":"2024121708080988100_ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-2823-2_1","article-title":"miRNA biogenesis and regulation of diseases: an updated overview","volume":"2595","author":"Vishnoi","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"6","key":"2024121708080988100_ref11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40291-016-0221-4","article-title":"Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects","volume":"20","author":"Backes","year":"2016","journal-title":"Mol Diagn Ther"},{"issue":"11","key":"2024121708080988100_ref12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2024121708080988100_ref13","first-page":"2098","article-title":"Down-regulation of miR-342-3p in hepatocellular carcinoma tissues and its prognostic significance","volume":"21","author":"Gao","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"2024121708080988100_ref14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1541-7786.MCR-17-0606","article-title":"Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progression","volume":"16","author":"Gowda","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2024121708080988100_ref15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jhep.2020.07.039","article-title":"MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma","volume":"74","author":"Komoll","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"2024121708080988100_ref16","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2012.15","article-title":"miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma","volume":"1","author":"Ding","year":"2012","journal-title":"Oncogenesis"},{"key":"2024121708080988100_ref17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.biopha.2017.05.092","article-title":"MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1","volume":"92","author":"Li","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2024121708080988100_ref18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/CBM-192399","article-title":"MiR-342 regulates cell proliferation and apoptosis in hepatocellular carcinoma through Wnt\/\u03b2-catenin signaling pathway","volume":"25","author":"Lu","year":"2019","journal-title":"Cancer Biomark"},{"issue":"3","key":"2024121708080988100_ref19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bbrc.2014.12.119","article-title":"miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-\u03baB pathway","volume":"457","author":"Zhao","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"2024121708080988100_ref20","first-page":"1","article-title":"miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1\/ATG14 pathway","author":"Hu","year":"2019"},{"issue":"1","key":"2024121708080988100_ref21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13000-018-0715-y","article-title":"Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer","volume":"13","author":"Yu","year":"2018","journal-title":"Diagn Pathol"},{"key":"2024121708080988100_ref22","article-title":"Downregulation of FOXP1 inhibits cell proliferation in hepatocellular carcinoma by inducing G1\/S phase cell cycle arrest","volume":"17","author":"Wang","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2024121708080988100_ref23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/jclinpath-2011-200547","article-title":"Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma","volume":"65","author":"Zhang","year":"2012","journal-title":"J Clin Pathol"},{"issue":"6","key":"2024121708080988100_ref24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2024121708080988100_ref25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"23","key":"2024121708080988100_ref26","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.3748\/wjg.v22.i23.5384","article-title":"Adjuvant sorafenib after heptectomy for Barcelona clinic liver cancer-stage C hepatocellular carcinoma patients","volume":"22","author":"Xia","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2024121708080988100_ref27","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12632","article-title":"Non-coding RNA MFI2-AS1 promotes colorectal cancer cell proliferation, migration and invasion through miR-574-5p\/MYCBP axis","author":"Li","year":"2019"},{"issue":"4","key":"2024121708080988100_ref28","first-page":"5243","article-title":"Overexpression of MYC binding protein promotes invasion and migration in gastric cancer","volume":"15","author":"Gong","year":"2018","journal-title":"Oncol Lett"},{"issue":"10","key":"2024121708080988100_ref29","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1111\/cas.14159","article-title":"EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating \u03b2-catenin at Ser552","volume":"110","author":"Zhu","year":"2019","journal-title":"Cancer Sci"},{"issue":"6","key":"2024121708080988100_ref30","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.7314\/APJCP.2015.16.6.2129","article-title":"Molecular mechanisms of apoptosis and roles in cancer development and treatment","volume":"16","author":"Goldar","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"2024121708080988100_ref31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2024121708080988100_ref32","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/bab.2233","article-title":"Caspase-3: structure, function, and biotechnological aspects","volume":"69","author":"Asadi","year":"2022","journal-title":"Biotechnol Appl Biochem"}],"container-title":["Toxicology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/13\/6\/tfae149\/61211037\/tfae149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/13\/6\/tfae149\/61211037\/tfae149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T08:08:33Z","timestamp":1734422913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxres\/article\/doi\/10.1093\/toxres\/tfae149\/7925783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/toxres\/tfae149","relation":{},"ISSN":["2045-4538"],"issn-type":[{"value":"2045-4538","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,11,5]]},"article-number":"tfae149"}}